The Aporia
Chafe, S. (2026, October 11). New belly fat injection cuts dangerous fat surrounding organs by 12% in early human trial. Fox News. https://www.foxnews.com/health/belly-fat-injection-cuts-dangerous-fat-surrounding-organs-12-percent-early-human-trial
Chafe, Sadie. “New belly fat injection cuts dangerous fat surrounding organs by 12% in early human trial.” Fox News, 11 Oct. 2026, https://www.foxnews.com/health/belly-fat-injection-cuts-dangerous-fat-surrounding-organs-12-percent-early-human-trial.
Chafe, Sadie. “New belly fat injection cuts dangerous fat surrounding organs by 12% in early human trial.” Fox News, October 11, 2026. https://www.foxnews.com/health/belly-fat-injection-cuts-dangerous-fat-surrounding-organs-12-percent-early-human-trial.
Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.
Early human trials of an experimental injection called CBL-514 have shown promise in reducing dangerous visceral fat deposits. Conducted by Dr. W. Timothy Garvey from the University of Alabama at Birmingham and Yu-Fang Ling from Caliway Biopharmaceuticals in New Taipei City, Taiwan, these studies involved administering 600 milligrams of CBL-514 to participants every three weeks for up to 12 weeks via injections into their lower abdomen. MRI scans revealed that those receiving the injection experienced a 12% reduction in visceral fat compared to an increase among those given a placebo. This development is significant as visceral fat, located deep inside the abdomen around internal organs, impacts metabolism and can contribute to insulin resistance and type 2 diabetes. The research also aligns with previous findings by the American Heart Association that indicated visceral fat has a stronger association with heart failure risk than BMI.